<DOC doc_id="AFP_ENG_20041007.0512" type="story">
<HEADLINE>
Vioxx competitors could also pose risks: studies
</HEADLINE>
<DATELINE>
WASHINGTON, Oct 7 (AFP)
</DATELINE>
<TEXT>
<S s_id="0">
Vioxx competitors could also pose risks: studies
</S>
<S s_id="1">
Anti-inflammatory drugs like Vioxx, which is being pulled off the market after it was linked to cardiac problems, could pose similar riskald of the University of Pennsylvania, who led one of the studies funded by the two pharmaceutical firms.
</S>
<S s_id="2">
"I believe this is a class effect" that includes similar types of medication, such as Celebrex or Bextra, FitzGerald said.
</S>
<S s_id="3">
Bextra, which hit the market in 2001, is Pfizer's newest pain medication.
</S>
<S s_id="4">
He urged the FDA to change information on packages to warn patients and doctors of the risks.
</S>
<S s_id="5">
Pfizer's medical director, Gail Cawkwell, said in a statement that "the data for Celebrex is robust and exceeds, in the length of patients in studies and in the size of studies, the data Vioxx has."
</S>
</TEXT>
</DOC>
